戻る
Carisma Therapeutics Inc (CARM)価格
CARM 株価推移チャート
CARM 収入
Carisma Therapeutics Inc
$0.04
-10.86%
$0
終値： Jan 23, 16:00:00 GMT-5
$0.04
0%
$0
アフターマーケット：Jan 23, 20:00:00 GMT-5
最新の利益結果: Q3 '25
報告済み: 2025-11-12
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
CARMの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Carisma Therapeutics Inc CARMの前四半期の収益はどうでしたか？
Carisma Therapeutics Incの収益見積もりはいくらですか？
Carisma Therapeutics Incの収益品質スコアはどれくらいですか？
Carisma Therapeutics Incはいつ収益を報告しますか？
Carisma Therapeutics Incの予想収益はいくらですか？
Carisma Therapeutics Incは収益予想を上回りましたか？
主要データ
前終値
$0.046
始値
$0.0414
当日レンジ
$0.0345 - $0.0437
52週レンジ
$0.026 - $1.27
取引高
442.7K
平均取引高
432.6K
1株当たり利益(TTM)
-1.18
配当利回り
--
時価総額
$1.7M
CARMとは何ですか？
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Philadelphia, Pennsylvania and currently employs 46 full-time employees. The company went IPO on 2014-02-06. The firm seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. The company is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.